RT vs TR-Cetuximab . Essai BONNER 213 patients Etude prospective randomisée

Cetuximab/RT > RT alone for

  - median duration of locoregional control (24,4 mois vs 14,9 mois) (hazard ratio for locoregianl progression or death, 0,68 ; P=0,005)

  - median duration of overall survival         (44 mois vs 29,3 mois)    (hazard ration for death, 0,74;                                              P=0,003)

  - progression free survival                                                                     (hazard ration for disease progression or death , 0,70;    P=0,006)

With the exception of acneiform rash and infusion reactions, the incidence of grade 3 or greater toxic effects, including mucositis, did not differ significantly between the two groups.

James A. Bonner

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

N Engl J Med 2006;354:567-78